Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.70 |
| ▸ | HTR2C | P28335 | 5/20 | 0.61 |
| ▸ | DRD3 | P35462 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | MLNR | O43193 | 2/20 | 0.61 |
| ▸ | HTR2B | P41595 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PNMT | P11086 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781608 | 0.86 | HTR6 (0.69) | HTR6HTR2CDRD3DRD2HTR2A | |
| SCHEMBL1961505 | 0.84 | HTR6 (0.65) | HTR6HTR2CDRD3DRD2HTR2A | |
| SCHEMBL1946627 | 0.83 | LMNA (0.77) | HTR6HTR2CDRD3DRD2HTR2A | |
| SCHEMBL5781306 | 0.82 | HTR6 (1.00) | HTR6HTR2CDRD3DRD2HTR2A | |
| SCHEMBL1945834 | 0.81 | HTR6 (0.85) | HTR6HTR2CDRD3DRD2HTR2A | |
| SCHEMBL1960721 | 0.80 | DRD2 (0.51) | HTR6HTR2CDRD3DRD2HTR2A | |
| SCHEMBL1958071 | 0.80 | HTR6 (0.70) | HTR6HTR2CDRD3DRD2HTR2A | |
| SCHEMBL6364800 | 0.80 | HTR2C (0.72) | HTR6HTR2CDRD3DRD2HTR2A | |
| SCHEMBL1957102 | 0.79 | KCNA1 (0.57) | HTR6HTR2CDRD3DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL1960794 | 0.79 | DRD2 (0.54) | HTR6HTR2CDRD3DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207160-B2 | Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1694334-B1 | TETRAHYDROBENZAZEPINES AND THEIR USE IN THE MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-10-19 | — | — | EP | disclosed |
| EP-2332543-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20090105224-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20050137186-A1 | Tetrahydrobenzazepines and their use | ABBOTT GMBH & CO. KG. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137186-A1 | Tetrahydrobenzazepines and their use | DRD3, ADRB3, AVPR1B | HTR6 115/4885HTR2C 30/4885DRD3 1/4885 |
| US-20090105224-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor | DRD3, DRD2, ADRB3 | HTR6 124/4885HTR2C 35/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.